HTBX News and Press, Heat Biologics Inc. From 06/04/21

DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Some people say that #timing does not matter, but it does.  If you were to #buyandhold Heat Biologics Inc (NASDAQ: HTBX) at a high, see it fall, and not be able to buy more on the dip like the big boys can, that would be troubling.  Over time, Stock Traders Daily has f...

Often, the action in a #stock is based on #investor perceptions, but it can be a circular event.  Not only is the #priceaction representative of perception, but it can influence perception too.  In the case of Heat Biologics Inc (NASDAQ: HTBX) we can see this in the charts.&#x...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...

Heat Biologics (HTBX) announces that the latest data from HS-110, the company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting, to be held next month.Shares up more than 12% premarket.HS-110 is...

DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, h...

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in several presentations and panel discus...

This is not EF Hutton, but it could be more #powerful.  A picture speaks a thousand words, they say, and the #priceaction of Heat Biologics Inc (NASDAQ: HTBX) tells an important story.  The movement tells us where investors perceive value, or the lack of it, and if we pay atte...

Heat Biologics ([[HTBX]] -1.8%) announces the appointment of Anthony Manning as the company's chief scientific advisor.Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics’ product portfolio.He brings over three decades of...